Daclizumab is a humanized monoclonal antibody that targets the IL-2 receptor α chain, and has shown promise as a novel treatment for multiple sclerosis (MS). Here, Wiendl and Gross provide an overview of clinical experience with daclizumab in MS, including results from phase II trials. They also discuss the putative mechanisms of action of this drug in MS pathogenesis, which involve dampening of early T-cell activation and upregulation of immunomodulatory natural killer cells.
- Heinz Wiendl
- Catharina C. Gross
